Trials / Terminated
TerminatedNCT01271166
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, dose finding, multicentre study evaluating the maximal tolerated dose of Glivec® in combination with mFOLFOX-Avastin®. Patients will be enrolled into each dose level in 3 patient cohorts. Additional cohorts will be enrolled, or dose levels opened, subject to the toxicities observed. Once the MTD has been determined the dose level below will be re-opened and extra patients, to a total of 15, will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-08-01
- First posted
- 2011-01-06
- Last updated
- 2011-01-06
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01271166. Inclusion in this directory is not an endorsement.